Sun Pharma Advanced Research, the research arm of India's top drug firm Sun Pharmaceuticals, said Wednesday it received U.S. Food and Drug Administration approval to market its epilepsy drug.
Japan's Takeda Pharmaceutical has looked at Indian companies in the vaccine space as it moves to tighten focus on that aspect of its business ahead of a Phase III trial for a dengue candidate and more broadly emerging markets as seen by a recent M&A deal in Turkey.
Enteris BioPharma is looking to make some money on the side of its drug-delivery operation, opening a contract manufacturing facility and scouting for clients.
Catalent is investing in infrastructure again, spending to flesh out its European network of storage and packaging facilities in response to an increase in demand on the continent.
Australia-based Cynata said it is on track to manufacture mesenchymal stem cells at a commercial scale after validation of its Cymerus MSC manufacturing technology and has an eye on companies in Japan as it seeks partnerships to reach the market.
Indonesia has long been active in providing vaccines to other developing countries, but now finds itself in a bind and turning to its state-owned and century-old pharmaceutical company, Bio Farma, to solve the nation's own growing need for vaccines.
Aquavit Life Sciences, a unit of Aquavit Pharmaceuticals of the United States, said it plans to build a research-and-development and production facility in a science and technology incubation center in South Korea.
Sun Pharma issued a recall of 3,363 bottles of its levetiracetam extended-release drug for treating epilepsy in the United States after the tablets failed dissolution tests.
Various recent reports covering the near-term and long-term outlook for the pharmaceutical industry in Asia paint a positive picture with increased revenues coming from the generics and biosimilars industries along with products as specific as human insulin from China.
A newly published study warns that Southeast Asia could soon see a spread of virulent new strains of drug-resistant malaria that already have spread much faster than experts had expected.